Frederic Lavie - Immunology, Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 63 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

SAFETY IN PATIENTS WITH LATENT TUBERCULOSIS WHO RECEIVED CONCOMITANT ANTITUBERCULOSIS MEDICATIONS: ANALYSIS OF 11 STUDIES OF GUSELKUMAB IN PSORIATIC DISEASE

Luis Puig, Tsen-Fang Tsai,Enrique R. Soriano,Tina Bhutani,Megan Miller, Alexa P. Kollmeier, Shu Li,Yin You, Hewei Li, Hetal Patel,Frederic Lavie,Melinda Gooderham, Angela Londono,Mark Lebwohl,Peter Nash

ACTA DERMATO-VENEREOLOGICA (2024)

引用0浏览0引用

Modulation of Interleukin-23 Signaling with Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders with Active Psoriatic Arthritis

Stefan Siebert,Laura C. Coates,Georg Schett,Siba P. Raychaudhuri,Warner Chen,Sheng Gao,Loqmane Seridi,Soumya D. Chakravarty,May Shawi,Frederic Lavie,Mohamed Sharaf,Miriam Zimmermann,Alexa P. Kollmeier,Xie L. Xu,Proton Rahman,Philip J. Mease,Atul Deodhar

ARTHRITIS & RHEUMATOLOGYno. 6 (2024): 894-904

引用0浏览0WOS引用

Multi-domain Effectiveness of Guselkumab Evaluated Via Composite Indices Through 1 Year in Patients with PsA and Inadequate Response to TNFi: Post Hoc Analysis of COSMOS

Laure Gossec,Xenofon Baraliakos,Daniel Aletaha,Mohamed Sharaf,Emmanouil Rampakakis,Frédéric Lavie, Clementina López-Medina,Carlo Selmi,Laura C Coates

Rheumatology (Oxford, England) (2024)

引用0浏览0WOS引用

AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK

U. Sbarigia,F. Zazzetti,Martine Lewi,Michel van Speybroeck, Teresa A. Simon, G. Li, Reyhan Sonmez, Christopher Carter,Chetan S. Karyekar, W. Noel,Manuel F. Ugarte‐Gil,Rocío V. Gamboa‐Cárdenas,Guillermo J. Pons‐Estel,Eduardo F. Borba, Loreto Massardo,Gustavo Aroca,R. Muñoz Louis,M. J. Moreno Álvarez,Ignacio García de la Torre,Isabel Acosta Colmán, Carolina Trujillo,Álvaro Danza,Kaleb Michaud,Patricia Katz,Rangi Kandane‐Rathnayake,Eric Morand,W. Louthrenoo,Y. H. Chen, J. Cho,Laniyati Hamijoyo,S. F. Luo,Y. J. Jan Wu,S Navarra, Z. Li,S. Sockalingam,Masayoshi Harigai, Z. Zhang,D. Basnayake, Michelle Chan, Tohru Takeuchi,Sang-Cheol Bae,F. Goldblatt,Stewart G. Neill, Kok-Why Ng,Nicola Tugnet, Sachin Kumar,Michael L. Tee, Y. Tanaka,C. S. Lau,Alberta Hoi, Mina Nickpour,Íñigo Rúa‐Figueroa,J. M. Pego-Reigosa,María Galindo,Jaime Calvo Alén, Antonio Fernández‐Nebro,R. Menor-Almagro,Frédéric Lavie

openalex（2024）

引用0浏览0引用

611 Advancing Data Harmonization in a Federated Model/network for Assessing Patient Characteristics in Systemic Lupus Erythematosus

Chetan S Karyekar,Federico Zazzetti, Teresa A Simon,Urbano Sbarigia,Frédéric Lavie,Enkeleida Nikaï,Martine Lewi,Michel van Speybroeck, Reyhan Sonmez, Chureen Carter

Lupus Science and Medicineno. Suppl 2 (2024)

引用0浏览0引用

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials

Philip Mease,Tatiana Korotaeva,Pavel Shesternya,Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov,Mohamed Sharaf,Frédéric Lavie,Atul Deodhar

Rheumatology and Therapy（2024）

引用0浏览0WOS引用

Patient Profiles in Randomised Controlled Trials Versus a Real-World Study, in Psoriatic Arthritis: Scoping Review and Meta-Analysis

Gelsomina Alle, Clementina Lopez-Medina, Stefan Siebert,Frédéric Lavie, Wim Noel, Josef S Smolen,Laure Gossec

The Journal of rheumatology (2024)

引用0浏览0WOS引用

Hurdles in New Drug Development in Rheumatic Diseases

Frederic Lavie,Terence Rooney

Joint Bone Spineno. 4 (2024): 105672-105672

引用0浏览0WOS引用

POS0943 GUSELKUMAB PROVIDES DURABLE IMPROVEMENTS IN PAIN AMONG PATIENTS WITH PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNFi: COSMOS PHASE 3b TRIAL

L. C. Coates,G. Schett,M. A. D’agostino,J. Ramírez, M. Sharaf,E. Rampakakis, M. Koivunen, M. Zimmermann,F. Lavie,P. S. Helliwell

Scientific Abstracts (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn